Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

Phase 1

Completed

• Conditions: Osteogenesis Imperfecta
• Interventions: Biological: Mesenchymal Stem Cells

• Registration Number: NCT02172885
• Lead Sponsor: Hospital de Cruces

Brief Summary

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

Detailed Description

The principal aim of this trial is to assess the safety of non-mutated HLA-identical Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of treatment with biphosphonates. Since MSC are inherently non-immunogenic and do not elicit proliferation of allogeneic lymphocytes (in co-culture experiments), a cell therapy based on HLA-identical or histocompatible (at least 5 shared out of 6 HLA antigens) allogenic MSC may be accomplished without subjecting the patients to immunosuppressor treatment. Adverse secondary effects due to immunosuppressor treatment will be avoided using this strategy thus patients may benefit from two cellular infusions. The patients will be followed for 2 years post their fifth and last MSC infusion.

Study Timeline

• Study Start: 2014-04
• Study First Submitted: 2014-06-12
• Study First Submitted QC: 2014-06-23
• Study First Posted: 2014-06-24
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-29
• Last Update Posted: 2023-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Patient age: older than 6 months and younger than 12 years old.
• Patients with molecular confirmation of mutation in either COL1A1 or COL1A2 genes associated with OI (type III).
• Patients with HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs.
• All patients that fulfil the inclusion criteria regardless of whether or not they are undergoing biphosphonate treatment.
• Patients whose parents or the legal guardians are willing to sign the consent forms to participate in this clinical trial.

Exclusion Criteria

• Patient age: older than 12 years old
• Patients lacking confirmation of mutation in either COL1A1 or COL1A2 genes associated with severe deforming OI (type III).
• Other pathological subtypes of OI.
• Patients lacking of HLA identical (that shared at least 5/6 antigens) siblings willing to donate bone marrow-MSCs.
• Immunodeficiencies and any other malignancies.
• Participation in other clinical trial.
• Any medical or psychiatric condition that in the researcher´s opinion could affect the patient´s ability to complete the trial or hamper the participation in the trial.
• Patients whose parents or the legal guardians do not sign the consent forms

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Mesenchymal stem cells	Mesenchymal Stem Cells	Five Mesenchymal Stem Cell infusions

Primary Outcome Measures

Name	Time	Method
Adverse Events as a Measure of Safety	up to 2 years post last MSCs infusion

Secondary Outcome Measures

Name	Time	Method
fracture rate	up to 2 years post last MSCs infusion
change from baseline in degree of functionality	up to 2 years post last MSCs infusion	9 question survey using a Bleck functional scale
bone mineral density	up to 2 years post last MSCs infusion
growth velocity	up to 2 years post last MSCs infusion
change from baseline in well-being	up to 2 years post last MSCs infusion	A 20 item questionnaire designed to evaluate the well-being will be used

Trial Locations

Locations (2)

Hospital Universitario Cruces; 🇪🇸 Barakaldo, Bizkaia, Spain

Hospital Universitario Getafe; 🇪🇸 Getafe, Madrid, Spain